HOME > Events > 詳細

2013/01/28

Target Validation and Zebrafish-based Systems Pharmacology

Target Validation and Zebrafish-based Systems Pharmacology
Toshio Tanaka MD, PhD
Department of Pharmacogenomics and Systems Pharmacology
Mie University Graduate School of Medicine

Although the rate of progress in preclinical biomedical science is high, it remains difficult to translate these findings into potential drug discovery. The major cause of attrition in the pharmaceutical industry is the lack of efficacy in phase II and III clinical trials, which may be due to insufficient target validation. Systems pharmacology is a recently introduced term that refers to the area dealing with the representation of therapeutics mechanisms of action and to improve the efficiency of innovative drug discovery and development. Previously, we reported that heme oxygenase-1 and heat shock protein 72 as potential drug targets by using rat model of cerebral vasospasm. However, there is serious problems of throughput in mammalian target validation system. In recent years in vivo chemical and genetic screening in zebrafish has emerged as a rapid and efficient method to identify drug target that modulate specific human disease processes. By performing primary screening of drug in vivo, the bioactivity, toxicity, and off-target side effects are determined from the onset of drug development. We would like to present our rencent data which suggest that zebrafish-based systems pharmacology will be powerful next generation strategy for therapeutic target validation.

UK-Japan Workshop programme

How do we identify new targets for new medicines?
28-29 January 2013

WORKSHOP OBJECTIVES
• Improve collaboration between researchers working on target validation (translational medicine) in the UK and Japan
• Highlight the importance of target validation in healthcare and to society at large
• Present leading developments in target validation from UK and Japan
• Identify the challenges facing target validation and how these challenges should be met
• Identify areas of collaboration and outline actions
• Give an overview of science policy relating to target validation

Mon 28 January – Closed workshop Day 1

Venue: New Hall, British Embassy Tokyo

*For security purpose, please show your passport or driving license at the security gate*

0845-0910 Registration and coffee (Presentation check for Session 1 & 2 speakers)

0910 Opening remarks (British Embassy)

Session 1: Scene Setting
*Each slot 25 minute presentation*

0915-0940 Prof Bountra (SBC Oxford)
To provide an introduction to the workshop, detailing the workshops overall objectives (What is target validation) and outlining it is important/challenge within drug discovery programmes.

0940-1005 Professor Toshio Tanaka (Mie University)
Academic Speaker

1005-1030 Dr Paul Chapman (Takeda)
Industry Speaker

1030–1045 Q&A and discussion

1045-1100 Coffee Break

Session 2: Current Overview of Research - Japan

OBJECTIVE(S):
• To provide an overview of current drug discovery process in Japan from academic, industrial, clinical perspectives.

Chair: Prof Toshio Tanaka (Mie University)

*Each slot 25 minute presentation*

1100-1125 Prof Toshio Miyata (Tohoku University)
AcademicSpeaker

1125-1150 Dr Masanari Itokawa (Tokyo Institute of Psychiatry)
Clinical Speaker

1150-1215 Professor Noriyasu Hirasawa (Tohoku University)
Academic Speaker

1215-1240 Dr Yoshiya Oda (Eisai)
Industrial Speaker

1240–1255 Q&A and discussion

1255-1400 Lunch

Session 3: Current Overview of Research – United Kingdom

OBJECTIVE(S):
• To provide an overview of current drug discovery process in the UK from academic, industrial and clinical perspectives.

Chair: Prof Chas Bountra (Oxford)

*Each slot 25 minute presentation*

1400-1425 Prof Anthony Hopkins (University of Dundee)
Academic Speaker

1425-1450 Dr Dayfdd Owen (Pfizer)
Industrial Speaker – Medicinal Chemistry Perspective

1450-1515 Dr Rab Prinjha (GSK)
Industrial Speaker
Possible topic – target progression – case study

1515-1540 Prof Praveen Anand (Imperial College London)
Clinical Speaker

1540–1555 Q&A and discussion

1555 -1610 Coffee Break

Session 4: Policy Considerations

Chair: Professor Bountra and Professor Miyata from Japan

*Each slot 20 minute presentation*

1610-1630 Prof Kurokawa (Keio University)
Japanese Policy perspective

1630-1650 Dr. Yamamoto (Cabinet Office)
Japanese Policy perspective

1650-1715 Professor Bountra
– UK Policy Perspective –

1715–1730 Q&A and discussion

1730 – CLOSE

1730 – 1900 Reception

Tue 29 January – Closed workshop Day 2 & Open Seminar

Workshop venue: New Hall, British Embassy Tokyo

*For security purpose, please show your passport or driving license at the security gate.

0845-0915 Registration and coffee (Presentation check for Session 4 speakers)

Session 5: What are the challenges and how can these be addressed?

OBJECTIVE(S):
• Identifying the gaps and challenges within Target Validation in relation to Drug Discovery
• identifying topics of mutual interest for collaboration or areas requiring the development of new scientific strategies
• establishing dialogue and means for achieving collaboration and joint projects

Chair: Professor Bountra and Professor Tanaka

0930-1100 Table Discussions
- Gaps/Challenges with Target Validation
- Solutions and Actions

1100-1115 Coffee Break

1115-1155 Summary Findings

1155-1200 Close and Group Photo

1200-1315 Lunch

1330 Workshop participants to move

Open seminar: ‘Challenges facing drug discovery in Japan and the UK – how can these challenges be met?’

OBJECTIVE(S):
• To provide an overview to a range of stakeholders on the current drug discovery processes in Japan and the UK.
• To create a forum for the open discussion of current challenges facing translational medicine and thoughts on how these should be addressed.

1400-1430 Registration

1430-1435 Opening remarks

1430-1450 Introduction to the session - Dr Dayfdd Owen (Pfizer)
• Provide a very brief introduction on Target Validation
• Summarise key points from previous 1.5 days
• Similarities/Differences between UK and Japan

1450-1510 Prof Chas Bountra (University of Oxford)
Drug discovery landscape in the UK

1510-1530 Dr Hirayama (MHLW)

1530-1545 Q&A

1545-1600 Coffee break

1600-1615 Prof Andrew Hopkins (University of Dundee) – academic perspective

1615-1630 Professor Toshio Miyata (Tohoku University)

1630-1645 UK speaker TBA

1645-1700 Professor Toshio Tanaka (Mie University)

1700-1715 Q&A

1715-1730 Closing remarks and move to reception hall

1730-1900 Networking reception